FUNCTIONAL INTERACTIONS OF IL2 AND TNF IN THE DIFFERENTIATION OF LGL INTO LAK EFFECTORS

被引：43

作者：

BLAY, JY ^{[1
]}

BERTOGLIO, J ^{[1
]}

FRADELIZI, D ^{[1
]}

CHOUAIB, S ^{[1
]}

机构：

[1] INST GUSTAVE ROUSSY,IMMUNOL LAB,CNRS,UA 1156,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE

来源：

INTERNATIONAL JOURNAL OF CANCER | 1989年 / 44卷 / 04期

关键词：

D O I：

10.1002/ijc.2910440407

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：598 / 604

页数：7

共 52 条

[1] CACHECTIN AND TUMOR-NECROSIS-FACTOR AS 2 SIDES OF THE SAME BIOLOGICAL COIN [J].

BEUTLER, B ;

CERAMI, A .

NATURE, 1986, 320 (6063) :584-588

[2]

BLAY JY, 1988, CR ACAD SCI III-VIE, V307, P47

[3] LABELING OF PROTEINS TO HIGH SPECIFIC RADIOACTIVITIES BY CONJUGATION TO A I-125-CONTAINING ACYLATING AGENT - APPLICATION TO RADIOIMMUNOASSAY [J].

BOLTON, AE ;

HUNTER, WM .

BIOCHEMICAL JOURNAL, 1973, 133 (03) :529-538

[4] ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].

CARSWELL, EA ;

OLD, LJ ;

KASSEL, RL ;

GREEN, S ;

FIORE, N ;

WILLIAMSON, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670

[5] ANALYSIS OF PROSTAGLANDIN-E2 EFFECT ON LYMPHOCYTE-T ACTIVATION - ABROGATION OF PROSTAGLANDIN-E2 INHIBITORY EFFECT BY THE TUMOR PROMOTOR 12.0 TETRADECANOYL PHORBOL-13 ACETATE [J].

CHOUAIB, S ;

ROBB, RJ ;

WELTE, K ;

DUPONT, B .

JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (02) :333-340

[6] GENERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS - SYNERGY BETWEEN TUMOR NECROSIS FACTOR AND INTERLEUKIN-2 [J].

CHOUAIB, S ;

BERTOGLIO, J ;

BLAY, JY ;

MARCHIOLFOURNIGAULT, C ;

FRADELIZI, D .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (18) :6875-6879

[7]

CHOUAIB S, 1985, J IMMUNOL, V134, P940

[8] CACHECTIN TUMOR NECROSIS FACTOR STIMULATES COLLAGENASE AND PROSTAGLANDIN-E2 PRODUCTION BY HUMAN SYNOVIAL-CELLS AND DERMAL FIBROBLASTS [J].

DAYER, JM ;

BEUTLER, B ;

CERAMI, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 162 (06) :2163-2168

[9]

EBERLEIN TJ, 1982, J EXP MED, V156, P385

[10]

ESPEVIK T, 1988, J IMMUNOL, V140, P2312

← 1 2 3 4 5 6 →